2025
PP01.20 Predictive Utility of Circulating Tumor DNA in First- Line Osimertinib Therapy for EGFR-Mutant Metastatic Lung Adenocarcinoma
Paredes R, Goto T, Litchman S, Gomez J, Doroshow D, Hirsch F, Veluswamy R, Marron T, Smith C, Rohs N, Rolfo C. PP01.20 Predictive Utility of Circulating Tumor DNA in First- Line Osimertinib Therapy for EGFR-Mutant Metastatic Lung Adenocarcinoma. Journal Of Thoracic Oncology 2025, 20: s9-s10. DOI: 10.1016/j.jtho.2025.03.025.Peer-Reviewed Original Research
2019
P2.01-22 ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib Therapy
Yu H, Goldberg S, Le X, Piotrowska Z, Smith P, Mensi I, Kirova B, Chmielecki J, Li-Sucholeicki X, Szekeres P, Doughton G, Patel G, Jewsbury P, Riess J. P2.01-22 ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib Therapy. Journal Of Thoracic Oncology 2019, 14: s647. DOI: 10.1016/j.jtho.2019.08.1366.Peer-Reviewed Original Research
2017
Complete clearance of plasma EGFR mutations as a predictor of outcome on osimertinib in the AURA trial.
Thress K, Markovets A, Barrett J, Chmielecki J, Goldberg S, Shepherd F, Vowler S, Oxnard G. Complete clearance of plasma EGFR mutations as a predictor of outcome on osimertinib in the AURA trial. Journal Of Clinical Oncology 2017, 35: 9018-9018. DOI: 10.1200/jco.2017.35.15_suppl.9018.Peer-Reviewed Original ResearchMedian progression-free survivalPlasma EGFR mutationsDetectable EGFR mutationsEGFR mutationsClinical outcomesOverall median progression-free survivalResponse ratePlasma samplesDurable response rateHeterogeneous resistance mechanismsObjective response ratePositive advanced NSCLCProgression-free survivalEGFR-TKI therapyPredictors of outcomeTyrosine kinase inhibitorsBaseline genotypingEvaluable baselinePositive genotypingAdvanced NSCLCPositive NSCLCCombination therapyEGFR-TKIsOsimertinib therapyComplete clearance
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply